Twist Bioscience Co. (NASDAQ:TWST) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Twist Bioscience Co. (NASDAQ:TWST) have been given an average recommendation of “Moderate Buy” by the ten research firms that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $53.80.

TWST has been the subject of a number of analyst reports. Leerink Partners upped their price objective on Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a research note on Thursday, October 17th. TD Cowen reissued a “buy” rating and set a $58.00 price target on shares of Twist Bioscience in a research report on Tuesday, November 26th. Robert W. Baird lifted their price objective on shares of Twist Bioscience from $48.00 to $54.00 and gave the stock an “outperform” rating in a research report on Tuesday. Scotiabank increased their target price on shares of Twist Bioscience from $54.00 to $62.00 and gave the company a “sector outperform” rating in a research report on Tuesday. Finally, JPMorgan Chase & Co. lifted their price target on shares of Twist Bioscience from $35.00 to $40.00 and gave the stock an “underweight” rating in a report on Tuesday.

Insiders Place Their Bets

In related news, Director Robert Chess sold 3,600 shares of the firm’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $47.26, for a total transaction of $170,136.00. Following the completion of the transaction, the director now owns 21,641 shares of the company’s stock, valued at $1,022,753.66. This trade represents a 14.26 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Emily M. Leproust sold 5,200 shares of the company’s stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $49.35, for a total value of $256,620.00. Following the completion of the sale, the chief executive officer now owns 667,318 shares in the company, valued at $32,932,143.30. The trade was a 0.77 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 59,002 shares of company stock valued at $2,851,681. Insiders own 3.01% of the company’s stock.

Institutional Trading of Twist Bioscience

A number of institutional investors and hedge funds have recently made changes to their positions in the business. ARK Investment Management LLC lifted its holdings in Twist Bioscience by 4.4% during the fourth quarter. ARK Investment Management LLC now owns 5,595,865 shares of the company’s stock valued at $260,040,000 after purchasing an additional 237,772 shares in the last quarter. State Street Corp raised its position in shares of Twist Bioscience by 19.9% during the 3rd quarter. State Street Corp now owns 3,167,353 shares of the company’s stock worth $143,101,000 after purchasing an additional 526,028 shares during the last quarter. Geode Capital Management LLC lifted its stake in Twist Bioscience by 1.9% in the 3rd quarter. Geode Capital Management LLC now owns 1,367,759 shares of the company’s stock valued at $61,807,000 after buying an additional 26,145 shares in the last quarter. Thrivent Financial for Lutherans acquired a new stake in Twist Bioscience in the 3rd quarter worth about $43,992,000. Finally, Wellington Management Group LLP increased its stake in Twist Bioscience by 188.5% during the 3rd quarter. Wellington Management Group LLP now owns 797,737 shares of the company’s stock worth $36,042,000 after buying an additional 521,272 shares in the last quarter.

Twist Bioscience Price Performance

Shares of Twist Bioscience stock opened at $53.70 on Friday. Twist Bioscience has a 1 year low of $27.41 and a 1 year high of $60.90. The stock has a market cap of $3.19 billion, a price-to-earnings ratio of -14.92 and a beta of 1.87. The firm’s 50-day moving average is $48.84 and its two-hundred day moving average is $46.32.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings data on Monday, February 3rd. The company reported ($0.53) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.62) by $0.09. The company had revenue of $88.70 million for the quarter, compared to analyst estimates of $86.96 million. Twist Bioscience had a negative net margin of 66.69% and a negative return on equity of 32.27%. Twist Bioscience’s revenue was up 24.1% compared to the same quarter last year. During the same period last year, the company posted ($0.75) earnings per share. On average, equities analysts expect that Twist Bioscience will post -2.27 earnings per share for the current year.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.